Zhezlova A V, Belolipetskaia V G, Blagodatskikh S V, Merkulova E V
Eksp Klin Farmakol. 2011;74(5):43-4.
An open randomized crossover test on 18 healthy volunteers was used to study the pharmacokinetics of anvifen (acting substance, aminophenylbutyric acid) manufactured in capsules at the Joint-Stock Company "Antiviral" (Russia). The test was performed after single peroral administration in comparison with phenibut tablets of the same manufacturer. The concentration of unchanged aminophenylbutiric acid in the blood plasma was measured by HPLC with UV detection. It is established that anvifen and phenibut are bioequivalent in terms of pharmacokinetics.
在18名健康志愿者身上进行了一项开放随机交叉试验，以研究俄罗斯“抗病毒”股份公司生产的胶囊剂型安维芬（活性物质，氨基苯基丁酸）的药代动力学。该试验在单次口服给药后进行，并与同一厂家生产的苯乙哌啶酮片作比较。采用高效液相色谱-紫外检测法测定血浆中未变化的氨基苯基丁酸浓度。结果表明，安维芬和苯乙哌啶酮在药代动力学方面具有生物等效性。
